Outcomes of Adjuvant Intravesical Mitomycin-C Treatment in Non-Muscle Invaziv High-Grade Bladder Cancer: Singe center experience

INTRODUCTION: The aim of the present study is to evaluate and report the clinical efficiacy of adjuvant intravesical mitomycin-c in the treatment of non-muscle invaziv high-grade bladder cancer patients of a tertiary single health-care center. MATERIAL and METHODS: Electronic records of the patients who had undergone endoscopic treatment of bladder tumors between Jan 2012 and Dec 2018 are retrospectively reviewed. Data of the patients who were diagnosed with non-invasive high-grade urothelial carcinoma are further evaluated if adjuvant intravesical mitomycin-c therapy had been initiated and included in the study. Patient demographics, cystoscopy findings, pathological findings, and outpatients record are included in the analysis. RESULTS: Total of 54 patients included in this study. Among them 50 patients had pT1 disease while 4 patients had pTa disease. None of the patients in this cohort had carcinoma-in-situ. Mean tumor diameter was 1.4 cm. Mean time from initial transurethral resection to the application of the adjuvant therapy was 2 weeks (1-4 weeks). Mean follow-up time was 21 months. During the follow-up, tumor progression was observed in 14 (26%) patients, high-grade tumor recurrence was observed in 22 (41%) patients, and low-grade tumor recurrence was observed in 4 (7%) patients. Among the 22 patients who had high-grade recurrence, 6 patients had also tumor progression during the follow-up Orijinal Çalışma 156 Adress for correspondence: Özer Ural Çakıcı, Yenimahalle Eğitim ve Araştırma Hastanesi, Üroloji Kliniği, Ankara Türkiye e-mail: ozerural@hotmail.com Available at www.actaoncologicaturcica.com Copyright ©Ankara Onkoloji Hastanesi DISCUSSION AND CONCLUSION: Non-invasive high-grade bladder cancer holds significant risk of stage progression and recurrence. The contemporary clinical guidelines endorse adjuvant intravesical BCG treatment in the management of non-muscle invasive bladder cancer. Due to our results, adjuvant intravesical mitomycin-c therapy can be considered as a accomplished alternative.